Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID J SHIH

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1134197429
CMS profile
278040
Location
NORTH DARTMOUTH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$260.78

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.47 2
Education $1.31 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID J SHIH

NPI 1134197429 · CMS profile ID 278040

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

NORTH DARTMOUTH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134197429?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID J SHIH, NPI 1134197429, CMS profile ID 278040. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134197429?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID J SHIH, NPI 1134197429, CMS profile ID 278040. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134197429?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID J SHIH, NPI 1134197429, CMS profile ID 278040, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1134197429?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $260.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $145.1712/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057294113 CMS
Travere Therapeutics, Inc. $1.3111/30/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059557811 CMS
AstraZeneca Pharmaceuticals LP $114.3009/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011344965 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.00 1
PY2020 $35.59 2
PY2022 $106.59 1
PY2023 $260.78 3
PY2024 $117.38 2
PY2025 $406.61 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,388,238.70 34
PY2024 Recipient $407.23 2
PY2024 Principal investigator $667,229.75 291
PY2023 Principal investigator $204,997.05 80

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $186.88 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195565
Principal investigator 1 Bausch Health US, LLC $27,035.78 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195567
Principal investigator 1 Bausch Health US, LLC $425.00 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195569
Principal investigator 1 Bausch Health US, LLC $170.72 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195573
Principal investigator 1 Bausch Health US, LLC $497.14 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195575
Principal investigator 1 Bausch Health US, LLC $188.68 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195577
Principal investigator 1 Bausch Health US, LLC $170.54 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195579
Principal investigator 1 Bausch Health US, LLC $176.86 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195581
Principal investigator 1 Bausch Health US, LLC $14,797.33 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195583
Principal investigator 1 Bausch Health US, LLC $213.96 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195585
Principal investigator 1 Bausch Health US, LLC $150.00 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195591
Principal investigator 1 Bausch Health US, LLC $188.68 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195593
Principal investigator 1 Bausch Health US, LLC $157.66 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195595
Principal investigator 1 Bausch Health US, LLC $232.30 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195597
Principal investigator 1 Bausch Health US, LLC $253.90 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195599
Principal investigator 1 Bausch Health US, LLC $180.78 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195601
Principal investigator 1 Bausch Health US, LLC $426.32 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195611
Principal investigator 1 Bausch Health US, LLC $180.78 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195613
Principal investigator 1 Bausch Health US, LLC $650.96 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195615
Principal investigator 1 Bausch Health US, LLC $5,968.49 12/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195617
Principal investigator 1 Bausch Health US, LLC $168.18 11/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195561
Principal investigator 1 Bausch Health US, LLC $234.50 11/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195563
Principal investigator 1 Bausch Health US, LLC $157.66 11/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195587
Principal investigator 1 Bausch Health US, LLC $157.66 11/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195589
Principal investigator 1 Bausch Health US, LLC $425.00 11/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195607
Principal investigator 1 Bausch Health US, LLC $405.00 10/27/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195571
Principal investigator 1 Bausch Health US, LLC $1,625.00 10/20/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195603
Principal investigator 1 Bausch Health US, LLC $186.88 10/20/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195609
Principal investigator 1 Bausch Health US, LLC $1,625.00 09/26/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195537
Principal investigator 1 Bausch Health US, LLC $186.88 09/26/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195541
Principal investigator 1 Bausch Health US, LLC $426.32 09/22/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195549
Principal investigator 1 Bausch Health US, LLC $188.68 09/08/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195533
Principal investigator 1 Bausch Health US, LLC $8,500.00 09/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195531
Principal investigator 1 Bausch Health US, LLC $170.72 09/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195555
Principal investigator 1 Bausch Health US, LLC $50.00 09/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195491
Principal investigator 1 Bausch Health US, LLC $445.25 09/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195505
Principal investigator 1 Bausch Health US, LLC $423.78 09/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195509
Principal investigator 1 Bausch Health US, LLC $188.68 08/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195495
Principal investigator 1 Bausch Health US, LLC $493.14 08/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195515
Principal investigator 1 Bausch Health US, LLC $425.00 08/04/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195507
Principal investigator 1 Bausch Health US, LLC $500.00 08/03/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195545
Principal investigator 1 Bausch Health US, LLC $194.86 08/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195503
Principal investigator 1 Bausch Health US, LLC $186.88 07/28/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195499
Principal investigator 1 Bausch Health US, LLC $168.18 07/28/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195539
Principal investigator 1 Bausch Health US, LLC $46.02 07/28/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195551
Principal investigator 1 Bausch Health US, LLC $11,401.03 07/25/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195527
Principal investigator 1 Bausch Health US, LLC $168.86 07/19/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195493
Principal investigator 1 Bausch Health US, LLC $750.00 07/13/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195497
Principal investigator 1 Bausch Health US, LLC $100.00 07/10/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195529
Principal investigator 1 Bausch Health US, LLC $100.00 07/10/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195535
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195501
Principal investigator 1 Bausch Health US, LLC $50.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195511
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195513
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195517
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195519
Principal investigator 1 Bausch Health US, LLC $50.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195521
Principal investigator 1 Bausch Health US, LLC $73.05 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195525
Principal investigator 1 Bausch Health US, LLC $35.50 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195543
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195553
Principal investigator 1 Bausch Health US, LLC $100.00 07/07/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195559
Principal investigator 1 Bausch Health US, LLC $300.00 07/06/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195523
Principal investigator 1 Bausch Health US, LLC $1,200.00 07/06/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195547
Principal investigator 1 Bausch Health US, LLC $125.00 07/06/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195557
Principal investigator 1 Bausch Health US, LLC $50.00 06/21/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195475
Principal investigator 1 Bausch Health US, LLC $50.00 06/14/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195471
Principal investigator 1 Bausch Health US, LLC $50.00 06/12/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195461
Principal investigator 1 Bausch Health US, LLC $572.86 06/12/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195465
Principal investigator 1 Bausch Health US, LLC $650.96 06/12/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195467
Principal investigator 1 Bausch Health US, LLC $300.00 06/09/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195459
Principal investigator 1 Bausch Health US, LLC $125.00 06/09/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195477
Principal investigator 1 Bausch Health US, LLC $50.00 06/05/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195469
Principal investigator 1 Bausch Health US, LLC $47.81 06/05/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195489
Principal investigator 1 Bausch Health US, LLC $50.00 05/31/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195487
Principal investigator 1 Bausch Health US, LLC $1,464.72 05/30/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195463
Principal investigator 1 Bausch Health US, LLC $32.10 05/30/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195473
Principal investigator 1 Bausch Health US, LLC $2,500.00 05/09/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195485
Principal investigator 1 Bausch Health US, LLC $3,535.28 05/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195479
Principal investigator 1 Bausch Health US, LLC $1,500.00 05/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195481
Principal investigator 1 Bausch Health US, LLC $12,000.00 05/01/2023 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055195483
Principal investigator 1 AstraZeneca Pharmaceuticals LP $97,232.85 02/02/2023 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 991124795